TG Therapeutics Inc (TGTX)
Profitability ratios
Return on sales
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 32.43% | 52.36% | 47.95% | 39.75% | 34.95% | -406.74% | -1,125.24% | -2,418.35% | -1,492.42% | -1,346.11% | -1,442.51% | -1,417.72% | -2,462.73% | -4,593.91% | -10,233.85% | -70,853.95% | -44,799.34% | -23,758.55% | -16,049.34% | -10,167.76% |
| Operating profit margin | -0.19% | 29.90% | 17.25% | 9.28% | -10.47% | -893.73% | -2,573.97% | -6,926.65% | -4,651.20% | -4,078.26% | -4,075.32% | -5,154.27% | -7,685.07% | -14,051.28% | -34,459.87% | -179,996.05% | -147,876.97% | -131,521.05% | -121,454.61% | -111,220.39% |
| Pretax margin | -5.29% | 28.12% | 14.85% | 5.87% | -14.32% | -930.62% | -2,662.36% | -7,124.10% | -4,749.83% | -4,144.49% | -4,126.45% | -5,204.07% | -7,784.36% | -14,271.13% | -35,158.99% | -183,802.63% | -151,798.68% | -135,198.03% | -124,230.26% | -113,730.26% |
| Net profit margin | -5.47% | 28.09% | 14.70% | 5.70% | -14.32% | -930.62% | -2,662.36% | -7,124.10% | -4,749.83% | -4,144.49% | -4,126.45% | -5,204.07% | -7,784.38% | -14,271.17% | -35,159.10% | -183,803.29% | -151,798.68% | -135,198.03% | -124,230.26% | -113,730.26% |
TG Therapeutics Inc's profitability ratios show a significant fluctuation over the past five quarters. The gross profit margin has ranged from a positive 32.43% to a negative 406.74%, indicating inconsistency in generating profits from sales after deducting the cost of goods sold.
Similarly, the operating profit margin has been highly volatile, fluctuating from a positive 29.90% to a negative 893.73%. This suggests that the company's operating expenses have varied significantly compared to its revenue generation, impacting its profitability.
The pretax margin and net profit margin have also shown erratic movements, ranging from positive figures to extremely negative percentages over the quarters. This indicates that the company has been facing challenges in managing its pre-tax and after-tax earnings relative to its total revenue.
Overall, the profitability ratios of TG Therapeutics Inc reflect a lack of consistency and stability in generating profits over the analyzed periods. Further investigation into the factors influencing these fluctuations would be necessary to understand the underlying issues affecting the company's financial performance.
Return on investment
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -0.09% | 25.38% | 12.95% | 6.26% | -5.72% | -76.38% | -82.57% | -99.62% | -107.27% | -112.80% | -106.41% | -90.82% | -82.65% | -70.46% | -56.96% | -43.73% | -82.08% | -67.85% | -181.26% | -103.71% |
| Return on assets (ROA) | -2.45% | 23.85% | 11.04% | 3.84% | -7.83% | -79.53% | -85.41% | -102.46% | -109.54% | -114.64% | -107.74% | -91.69% | -83.72% | -71.56% | -58.12% | -44.66% | -84.25% | -69.75% | -185.40% | -106.05% |
| Return on total capital | 0.09% | 36.67% | 18.83% | 7.92% | -7.18% | -122.10% | -131.49% | -148.65% | -136.19% | -143.39% | -135.69% | -113.43% | -108.70% | -88.53% | -70.19% | -51.91% | -121.02% | -92.36% | -662.92% | -250.14% |
| Return on equity (ROE) | -7.48% | 53.89% | 25.73% | 7.90% | -15.72% | -434.22% | -614.42% | -338.53% | -237.54% | -223.58% | -191.61% | -146.78% | -110.10% | -89.92% | -71.62% | -53.79% | -135.20% | -105.80% | — | -447.68% |
TG Therapeutics Inc's profitability ratios have shown significant variability over the past years.
- Operating return on assets (Operating ROA) has fluctuated from negative to positive values, indicating the company's ability to generate profit from its assets was inconsistent.
- Return on assets (ROA) has also been volatile, with periods of negative returns and occasional spikes in profitability, suggesting varying levels of efficiency in asset utilization.
- Return on total capital shows a similar trend, with fluctuations in profitability ranging from negative to positive percentages, reflecting changes in the company's ability to generate profits from its invested capital.
- Return on equity (ROE) has shown the highest variability, with negative returns in most periods, signaling challenges in generating profits for the shareholders.
Overall, the company's profitability ratios reflect instability and inconsistency in its financial performance, indicating the need for closer scrutiny and potential strategic adjustments to enhance profitability and shareholder value.